IO360 Summit
Dates : March 24 – March 26 2025 Location : Boston, MA Link : https://io360summit.com
Posts by Vincent
Egle Therapeutics receives €9.3 Million in State Funding Under the “Innovations in Biotherapies and Bioproduction” Call for Projects from France 2030
Egle Therapeutics receives significant non-dilutive funding to accelerate the clinical development of its lead immuno-oncology therapeutic candidate, EGL-001, as part of the “Innovations in Biotherapies and Bioproduction” call for projects…
EGLE Therapeutics Strengthens its Executive Leadership team with the Appointment of Christophe Quéva, Ph.D, as Chief Executive Officer
Paris, France, January 13th, 2025 – Egle Therapeutics, a clinical-stage biotechnology company advancing the next generation of regulatory T cell (Treg)-focused therapies for oncology and autoimmune diseases, today announced the…
Society for Immunotherapy of Cancer (SITC)
Location: Houston, USA Dates: November 6-10, 2024
Egle Therapeutics to share preclinical efficacy data for EGL-001, a CTLA-4/CD25 antagonist fusion protein at the Society for Immunotherapy of Cancer Meeting
Egle Therapeutics, a biotechnology company focused on advancing the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, will present at the Society for Immunotherapy of Cancer Meeting…
ESMO
Location: Barcelona, Spain Dates: September 13-17, 2024
EGLE Therapeutics Strengthens its Board of Directors with the Appointment of Michel Detheux, Ph.D, as Independent Chairman Board Member, and with the Appointment of Mojgan Hossein-Nia, Ph.D. as Board member representative of Takeda Ventures
EGLE Therapeutics Strengthens its Board of Directors with the Appointment of Michel Detheux, Ph.D, as Independent Chairman Board Member, and with the Appointment of Mojgan Hossein-Nia, Ph.D. as Board member…
Interleukin-2 | The Promise of IL-2 Therapy
Location: Paris France Dates: September 4-7, 2024
Egle Therapeutics to share preclinical data for its first autoimmune disease program, EGL-003, with an oral presentation at the 2024 Promise of Interleukin-2 Therapy Meeting
Egle Therapeutics, a biotechnology company focused on advancing the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, will deliver an oral presentation at The Promise of Interleukin-2…